Zepatier is designed to treat hepatitis C genotypes 1 and 4. The drug does not require the use of interferon, according to the report. Merck’s newly approved drug will compete with Gilead Sciences’ Harvoni and AbbVie’s Viekira Pak.
More articles on gastroenterology:
4 GI physicians in the news – Jan. 29, 2016
Proudest moments in GI: One gastroenterologist’s career high points
Sedation ups colonoscopy risk: 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
